Combining bioreductive drugs and radiation for the treatment of solid tumors

Seminars in Radiation Oncology

Volumn 13, Issue 1, 2003, Pages 42-52

  Stratford, Ian J ^a   Williams, Kave J ^a   Cowen, Rachel L ^a   Jaffar, Mohammed ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; BIOREDUCTIVE DRUG; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIN; ETANIDAZOLE; HETEROCYCLIC COMPOUND; METRONIDAZOLE; MISONIDAZOLE; MITOMYCIN C; MUP 98176; NIMORAZOLE; NITROFURAL; PIMONIDAZOLE; PORFIROMYCIN; PRODRUG; QUINONE DERIVATIVE; RADIOSENSITIZING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SN 23862; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIC CELL; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REDUCTION; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS;

EID: 0037267664     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2003.50008     Document Type: Review

References (83)

1. Workman P, Stratford IJ: The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Met Rev 12:73-82, 1993
2. Brown MJ, Siim BG: Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 6:22-36, 1996
3. Denny WA, Wilson WR, Hay MP: Recent developments in the design of bioreductive drugs. Br J Cancer 74, S32-S38, 1996
4. Stratford IJ, Workman P: Bioreductive drugs into the next millennium. Anti-Cancer Drug Design 13:519-528, 1998
5. Rauth AM, Melo T, Misra V: Bioreductive therapies: An overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 42:755-762, 1998
6. Wardman P: Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8:739-761, 2001
7. Wouters BG, Weppler SA, Koritzinsky M, et al: Hypoxia as a target for combined modality treatments. Eur J Cancer 38:240-257, 2002
8. Sutherland RM: Selective chemotherapy of non-cycling cells in an in vitro tumour model. Cancer Res 34:3501-3503, 1974
9. Kennedy KA, Teicher BA, Rockwell S, et al: The hypoxic tumor cell: A target for selective cancer chemotherapy. Biochem Pharmacol 29:1-8, 1980.
10. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumours: presidential address. Cancer Res.48:775-778, 1988
11. Mohindra JK, Rauth AM: Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res 36:930-936, 1976
12. Wardman P: The chemistry of nitroarene and aromatic N-oxide radicals, in Alfassi ZB (ed): The chemistry of N-centred radicals. New York, John Wiley, 1998, pp 98-126
13. Stratford IJ: Split dose cytotoxic experiments with misonidazole. Br J Cancer 38:130-136, 1978
14. Taylor YC, Rauth AM: Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro. Br J Cancer 41:892-900, 1980
15. Koch CJ: Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53:3992-3997, 1993
16. von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351-1359, 2000
17. Walton MI, Workman P: Nitroimidazole bioreductive metabolism: Quantitation and characterisation of mouse tissue benzonidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 36:887-896, 1987
18. Patterson AV, Saunders MP, Chinje EC, et al: Overexpression of human NADPH: Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76:1338-1347, 1997
19. Walton MI, Workman P: Enzymology of the reductive bioactivation of SR 4233: A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39:17351742, 1990
20. Patterson AV, Barham HM, Chinje EC, et al: Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72:1144-1150, 1995
21. Saunders MP, Jaffar M, Patterson AV, et al: The importance of P450 reductase for determining the sensitivity of human tumour cells to the indolequinone E09 and related analogues lacking functionality in the C-2 and C-3 positions. Biochem Pharmacol 59:993-996, 2000
22. Bridgewater JA, Springer CJ, Knox RJ, et al: Expression of the bacterial nitroreductases enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 31:2362-2370, 1995
23. Airley R, Loncaster J, Davidson S, et al: Glucose transporter Glut-1 expression correlates with tumour hypoxia and predicts metastasis free survival in advanced carcinoma of the cervix. Clin Cancer Res 7:928-934, 2001
24. Loncaster JA, Harris AL, Davison SE, et al: CA IX expression, a potential new intrinisic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394-6399, 2001
25. Brown JM, Yu NY, Cory MJ, et al: In vivo evaluation of the radio-sensitizing and cytotoxic properties of newly synthesized electron-affinic drugs. Br J Cancer 37:206-211, 1978 (suppl)
26. Stewart F: The effects of hyperthermia and ionizing radiation on bladder, skin and an experimental tumour in mice [doctoral thesis]. London, University of London, 1978
27. Taylor YC, Rauth AM: Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and CHO cells. Cancer Res 38:2745-2752, 1978
28. Rockwell S: Effects of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 38:229-235, 1986
29. Stratford IJ, O'Neill P, Sheldon PW, et al: RSU 1069, a nitroimidazole containing an aziridine group: Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 35:105-110, 1986
30. O'Neill P, McNeil SS, Jenkins TC: Induction of DNA crosslinks in vitro upon reduction of the nitroimidazoleaziridines RSU-1069 and RSU-1131 Biochem Pharmacol 36:1787-1792, 1987
31. Stratford IJ, Adams GE, Godden J, et al: Induction of tumour hypoxia post-irradiation: A method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 55:411-422, 1989
32. Stratford J: Bioreductive drugs in cancer therapy. Br J Radiol 24:128-136, 1992 (suppl)
33. Horwich A, Holliday SB, Deacon JM, et al: A toxicity and pharmacokinetics study in man of the hypoxic radiosensitizer RSU-1069. Br J Radiol 59:1238-1240, 1986
34. Bremner JC: Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: With particular reference to in vivo methods of evaluation. Cancer Met Rev 12:177-193, 1993
35. Jenkins T, Naylor MA, O'Neill P, et al: Synthesis and evaluation of alpha-[)2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33:2603-2610, 1990
36. Binger M, Workman P: Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-ni-tro-1H-imidazole-1-ethanol (RSU 1069). Cancer Chem Pharmacol 29:37-47, 1991
37. Lee AE, Wilson WR: Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 163:50-59, 2000
38. Zeman EM, Brown JM, Lemmon MJ, et al: SR-4233: A new bioreactive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1968
39. Zeman EM, Hirst VK, Lemmon MJ, et al: Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12:209-218, 1988
40. Zeman EM, Brown JM: Pre-and post-irradiation radiosensitization by SR 4233. Int J Rad Oncol Biol Phys 16:967-971, 1989
41. Biedermann KA, Wang J, Graham RP, et al: SR4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer 63:358-362, 1991
42. Wang J, Biedermann KA, Brown JM: Repair of DNA and chromosome breaks in cells exposed to SR4233 under hypoxia and to ionising radiation. Cancer Res 52:4473-4477, 1992
43. Stratford IJ, Stephens MA: The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16:973-976, 1989
44. Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res 50:7745-7749, 1990
45. Dorie MJ, Menke D, Brown JM: Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys 28:145-150, 1994
46. Brown JM, Giaccia AJ: Tumour hypoxia: The picture has changed in the 1990s. Int J Radiat Biol 65:95-102, 1994
47. Hill RP: Sensitizers and radiation close fractionation: Results and interpretations. Int J Radiat Oncol Biol Phys 12:1049-1054, 1986
48. Brown JM, Lemmon MJ: Fractionation increases the antitumour effect of adding a hypoxic cytotoxin to irradiation, in Dewey WC (ed): Radiation research a twentieth century perspective. San Diego, CA, Academic, 1992, pp 807-812
49. Rockwell S, Sartorelli AC: Mitomycin C and radiation, in Hill BT (ed): Antitumor drug-radiation interactions. Boca Raton, FL, CRC Press, Inc, 1990, pp 126-139
50. Weissberg JB, Papac RJ, Son YH, et al: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 17:3-9, 1989
51. Haffty BG, Son YH, Sasaki CT, et al: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 27:241-250, 1994
52. Rockwell S, Keyes SR, Sartorelli AC: Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 116:100-113, 1988
53. Belcourt MF, Hodnick WF, Rockwell S, et al: Exploring the mechanistic aspects of mitomycing antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: Cytochrome C (P450) reductase and DT-diaphorase. Adv Enzyme Regul 38:111-133, 1998
54. Powis G: Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther 35:57-162, 1987
55. Keyes SR, Fracasso PM, Heimbrook DC, et al: Role of NADPH: Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Research 44:5638-5643, 1984
56. Haffty BG, Son YH, Wilson LD, et al: Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5:235-245, 1997
57. Robertson N, Haigh A, Adams GE, et al: Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A:1013-1019, 1994
58. Plumb JA, Workman P: Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56:134-139, 1994
59. Adams GE, Stratford IJ: Bioreductive drugs for cancer therapy: The search for tumor specificity. Int J Radiat Oncol Biol Phys 29:231-238, 1994
60. Jaffar M, Naylor MA, Robertson N, et al: 5-Substituted analogues of 3-hydroxymethyl-1-5-arziridinyl-1-methyl-2-[1H-indole-4, 7-dione]prop-2-en-ol (E09, NSC 382459) and their regiosomers as hypoxia-selective agents: Structure-cytotoxicity in vitro. Anticancer Drug Des 13:105-123, 1998
61. Smitskamp-Wilms E, Hendriks HR, Peters GJ: Development, pharmacology, role of DT-diaphorase and prospects of the indolequinone EO9. Gene Pharmacol 27:421-429, 1996
62. Schellens JH, Planting AS, van Acker BA, et al: Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Nat Cancer Inst 86:906-912, 1994
63. Pavlidis N, Hanauske AR, Gamucci T, et al: A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG). Ann Oncol 7:529-531, 1996
64. Patterson LH: Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding: A new class of bioreductive agent. Cancer Met Rev 12:119-134, 1993
65. McKeown SR, Hejmadi MV, McIntyre IA, et al: AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 72:76-81, 1995
66. McKeown SR, Friery OP, McIntyre IA, et al: Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 27:S39-42, 1996 (suppl)
67. Patterson LH, McKeown SR, Robson T, et al: Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des Dec 14:473-486, 1999
68. Everett SA, Naylor MA, Patel KB, et al: Bioreductivelyactivated prodrugs for targeting hypoxic tissues: Elimination of Aspirin from 2-nitroimidazole derivatives. Bio Med Chem Lett 9:1267-1272, 1999
69. McNally VA, Patterson AV, Williams KJ, et al: Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours. Curr Pharm Des 1319-1333, 2002
70. Wardman P, Derris MF, Everett SA: Radicals from oneelectron reduction of nitro compounds, aromatic-N-oxides and quinones: The kinetic basis for hypoxia-selective bioreductive drugs. Biochem Soc Symp 61:171-178, 1995
71. Marshall RS, Rauth AM: Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in chinese hamster ovary cells and in a repair deficient mutant. Cancer Res 46:2709-2713, 1986
72. Mulcahy RT: Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. Cancer Res 44:4409-4413, 1984
73. Hall EJ: Radiobiology for the radiologist. Lippincott, New York, 1988, p 143.
74. Brown JM: SR 4233 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993
75. Butler J, Sparswick VJ, Cummings J: The autooxidation of the reduced forms of E09. Free Radical Res 25:141-148, 1996
76. Shibata T, Giaccia AJ, Brown JM: Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4:40-48, 2002
77. Patterson AV, Williams KJ, Cowen RL, et al: Oxygensensitive gene-directed enzyme-prodrug therapy (02-GDEPT) for solid tumours: Potentially curative when combined with x-rays. Gene Ther 9:946-954, 2002
78. Overgaard J, Hansen HS, Overgaard M, et al: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135-146, 1998
79. Damen EW, Nevalainen TJ, van den Bergh TJ, et al: Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg Med Chem. 10(1):71-77, 2002
80. Papadopoulou MV, Ji M, Rao MK, et al: 4-[3-(2-Nitro-1imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: Comparison with tirapazamine. Oncol Res 12:323-333, 2000
81. Tercel M, Lee AE, Hogg A, et al: Hypoxia-selective anti-tumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 11:3511-3522, 2001
82. Gali-Muhtasib HU, Haddadin MJ, Rahhal DN, et al: Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. Oncol Rep 8:679-684, 2001
83. Sun ZY, Botros E, Su AD, et al: Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins. J Med Chem 43:4160-4168, 2000